1. Category: Electronic Data Capture (EDC)

    1-15 of 85 // 1 2 3 4 5 6 »
    1. How Does Big Pharma Boost Its Returns?

      Explore Fool.com (Feb 19 2012)

      Break it down with the DuPont Formula.

      Comment Mentions:   FDA   GlaxkSmithKline plc   Novartis International AG

    2. Deadly bird flu studies to stay secret for now: WHO

      Explore reuters.com (Feb 17 2012)

      GENEVA/LONDON (Reuters) - Two studies showing how scientists mutated the H5N1 bird flu virus into a form that could cause a deadly human pandemic will be published only after experts fully assess the risks, the World Health Organization (WHO) said on Friday.

      Comment

    3. Why Bristol-Myers Squibb Could Break Out This Year

      Explore The Motley Fool (Feb 15 2012)

      Why Bristol-Myers Squibb Could Break Out This Year

      Comment Mentions:   FDA   Merck & Co Inc   Bristol-Myers Squibb

    4. 19 Clinical Trials Aren't Enough

      Explore Fool.com (Jan 20 2012)

      The FDA rejects Bristol-Myers and AstraZeneca's dapagliflozin.

      Comment Mentions:   FDA   AstraZeneca   The Food and Drug Administration

    5. Medidata: Integrating Infrastructure for Clinical Trials

      Explore Bio-IT World (Jan 18 2012)

      Bio-IT World | Glen de Vries thought he would be teaching biology or chemistry in college, but somewhere en route to a satisfying career in academic research, he got distracted. Bio•IT World chief editor Kevin Davies spoke to de Vries about the progress of Medidata and the state of e-clinical technology in general.

      Comment Mentions:   SAP   Kevin Davies, Ph.D.   Medidata

    6. Perceptive Informatics DataLabs EDC Solution Implemented by 15 of the top Global Biopharmaceutical Companies

      Explore Industry (Dec 30 2011)

      News Brief | This latest milestone was preceded by an independent report from Industry Standard Research, which ranked the DataLabs EDC solution the highest in overall satisfaction among EDC solutions in a survey of principal investigators and site coordinators.

      Comment Mentions:   Parexel International   Perceptive Informatics   PAREXEL International PAREXEL International Corporation

    7. Whoa! These Stocks Spread Some Holiday Cheer

      Explore Fool.com (Dec 27 2011)

      These stocks just took off, but are they about to make a return trip to Earth?

      Comment Mentions:   FDA   Bristol-Myers Squibb

    8. The News That Moved the Market Today

      Explore Fool.com (Dec 27 2011)

      Breaking down the market.

      Comment Mentions:   FDA

    9. Venezuela offers free removal of PIP breast implants

      Explore reuters.com (Dec 27 2011)

      CARACAS (Reuters) - Venezuela is offering women the free removal of breast implants made by a bankrupt French company that used industrial silicone to make cheap prostheses linked to health risks.

      Comment Mentions:   FDA

    10. Bulk of company's implants used subpar silicone

      Explore reuters.com (Dec 27 2011)

      TOULON, France (Reuters) - The lawyer for the French company at the heart of an escalating global breast implant scare told Reuters on Tuesday that most of the protheses sold by the firm since 1991 were produced using a non-approved silicone.

      Comment Mentions:   FDA

    11. Many seriously ill get too much care: docs, nurses

      Explore reuters.com (Dec 27 2011)

      NEW YORK (Reuters Health) - A third of doctors working in intensive care units (ICUs) believe one or more of their patients is getting inappropriate care, with slightly fewer nurses sharing the sentiment, a European poll shows.

      Comment Mentions:   FDA   American Medical Association

    12. 2011 No Dreamboat for MannKind

      Explore Fool.com (Dec 27 2011)

      An FDA rejection and a long wait is a bad combination.

      Comment Mentions:   FDA   Pfizer Inc   Novo Nordisk A/S

    13. Exelixis 2011: Not What the Doctor Ordered

      Explore Fool.com (Dec 27 2011)

      A tale of an inability to get a Special Protocol Assessment from the FDA.

      Comment Mentions:   FDA   AstraZeneca   Dendreon

    14. FDA moves forward with new Repros Therapeutics therapy

      Explore Business News (Dec 27 2011)

      The U.S. Food and Drug Administration is in agreement with Repros Therapeutics Inc. (Nasdaq:RPRX) on how to move forward in approaching the development of a new testosterone production therapy, according to a release from the company on Tuesday. The therapy, Androxal, produces testosterone levels in the normal range for men while helping them maintain sperm count. Repros Therapeutics President and CEO Joseph Podolski said products currently on the market that treat testosterone deficiencies typically decrease sperm count...

      Comment Mentions:   FDA

    15. Mylan wins OK for anti-seizure generic drug

      Explore Business News (Dec 27 2011)

      Southpointe-based Mylan Inc. has received the go-ahead from the U.S. Food and Drug Administration to market a generic Keppra XR extended release tablet to treat epileptic seizures. The FDA approval to Mylan Pharmaceuticals, a unit of Mylan Inc. (Nasdaq: MYL), is under the abbreviated new-drug application/first-to-file program. The product name is Levetiracetam Extended-Release (ER) Tablets, 500 mg and 750 mg, the generic of UCB's Keppra XR. There were sales of $162.8 million for the year ended Sept...

      Comment Mentions:   FDA

    16. 1-15 of 85 // 1 2 3 4 5 6 »